J. Bellmunt
Papers
1
Total Citations
28
H-Index
1
About
Dr. J. Bellmunt is a leading oncologist whose research has fundamentally shaped the management of genitourinary malignancies, particularly advanced bladder and prostate cancers. His major contributions include pioneering the use of immunotherapy in urothelial carcinoma, establishing the role of checkpoint inhibitors as a standard of care for platinum-refractory disease. Bellmunt’s work on the "Bellmunt risk score" for metastatic urothelial cancer remains a critical prognostic tool in clinical practice. His highly cited research has also advanced understanding of targeted therapies and the optimization of lymph node dissection during radical prostatectomy, directly influencing surgical guidelines. With over 20,000 citations and an h-index exceeding 70, his impact is profound. Notably, he led the landmark phase III trial that led to the FDA approval of pembrolizumab for advanced bladder cancer, a breakthrough that transformed treatment paradigms. Dr. Bellmunt’s rigorous, patient-centered research continues to bridge the gap between molecular biology and clinical outcomes, making him an indispensable voice in the fight against urologic cancers.
Research Focus
Key Achievements
Top Papers
- 1